The Biology and Pharmacology of Calcium Channel α2-δ Proteins Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA November 10, 2003

Charles P. Taylor, William A. Catterall, Franz Hofmann, Z. David Luo, David J. Wustrow, Michael Vasko, Mark Field, Scott Baron

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Overall, these presentations reviewed the current state of α2-δ biology and pharmacology. The presentations describing structure-activity studies and mutation studies of drug binding to α2-δ indicated that high-affinity binding of pregabalin and related compounds to α2-δ type 1 protein is necessary for pharmacological actions in models of analgesic, anxiolytic, and anticonvulsant action. These findings suggest that drugs that act by binding to the α2-δ proteins define a novel class of centrally-acting drugs that are fundamentally different from other kinds of anticonvulsant, analgesic or anxiolytic drugs. It is thought that these α2-δ ligand drugs act by reducing the synaptic release of excitatory neurotransmitters and neuromodulators in the brain or spinal cord, particularly when synapses are abnormally hyperactive, or when cytosolic proteins are phosphorylated by protein kinase C or protein kinase A activation.

Original languageEnglish
Pages (from-to)183-188
Number of pages6
JournalCNS Drug Reviews
Volume10
Issue number2
StatePublished - Jun 2004

Fingerprint

Calcium Channels
Pharmacology
Pharmaceutical Preparations
Anti-Anxiety Agents
Proteins
Anticonvulsants
Neurotransmitter Agents
Analgesics
Cyclic AMP-Dependent Protein Kinases
Synapses
Spinal Cord
Ligands
Mutation
Brain

Keywords

  • α-δ Proteins
  • Analgesics
  • Anticonvulsants
  • Calcium channels
  • Gabapentin
  • Pregabalin
  • R217A mice

ASJC Scopus subject areas

  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

The Biology and Pharmacology of Calcium Channel α2-δ Proteins Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA November 10, 2003. / Taylor, Charles P.; Catterall, William A.; Hofmann, Franz; Luo, Z. David; Wustrow, David J.; Vasko, Michael; Field, Mark; Baron, Scott.

In: CNS Drug Reviews, Vol. 10, No. 2, 06.2004, p. 183-188.

Research output: Contribution to journalArticle

Taylor, Charles P. ; Catterall, William A. ; Hofmann, Franz ; Luo, Z. David ; Wustrow, David J. ; Vasko, Michael ; Field, Mark ; Baron, Scott. / The Biology and Pharmacology of Calcium Channel α2-δ Proteins Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA November 10, 2003. In: CNS Drug Reviews. 2004 ; Vol. 10, No. 2. pp. 183-188.
@article{9077cd91a7124258a1042fce3fd839d6,
title = "The Biology and Pharmacology of Calcium Channel α2-δ Proteins Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA November 10, 2003",
abstract = "Overall, these presentations reviewed the current state of α2-δ biology and pharmacology. The presentations describing structure-activity studies and mutation studies of drug binding to α2-δ indicated that high-affinity binding of pregabalin and related compounds to α2-δ type 1 protein is necessary for pharmacological actions in models of analgesic, anxiolytic, and anticonvulsant action. These findings suggest that drugs that act by binding to the α2-δ proteins define a novel class of centrally-acting drugs that are fundamentally different from other kinds of anticonvulsant, analgesic or anxiolytic drugs. It is thought that these α2-δ ligand drugs act by reducing the synaptic release of excitatory neurotransmitters and neuromodulators in the brain or spinal cord, particularly when synapses are abnormally hyperactive, or when cytosolic proteins are phosphorylated by protein kinase C or protein kinase A activation.",
keywords = "α-δ Proteins, Analgesics, Anticonvulsants, Calcium channels, Gabapentin, Pregabalin, R217A mice",
author = "Taylor, {Charles P.} and Catterall, {William A.} and Franz Hofmann and Luo, {Z. David} and Wustrow, {David J.} and Michael Vasko and Mark Field and Scott Baron",
year = "2004",
month = "6",
language = "English",
volume = "10",
pages = "183--188",
journal = "CNS Drug Reviews",
issn = "1080-563X",
publisher = "Neva Press, Inc.",
number = "2",

}

TY - JOUR

T1 - The Biology and Pharmacology of Calcium Channel α2-δ Proteins Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting Sheraton New Orleans Hotel New Orleans, LA November 10, 2003

AU - Taylor, Charles P.

AU - Catterall, William A.

AU - Hofmann, Franz

AU - Luo, Z. David

AU - Wustrow, David J.

AU - Vasko, Michael

AU - Field, Mark

AU - Baron, Scott

PY - 2004/6

Y1 - 2004/6

N2 - Overall, these presentations reviewed the current state of α2-δ biology and pharmacology. The presentations describing structure-activity studies and mutation studies of drug binding to α2-δ indicated that high-affinity binding of pregabalin and related compounds to α2-δ type 1 protein is necessary for pharmacological actions in models of analgesic, anxiolytic, and anticonvulsant action. These findings suggest that drugs that act by binding to the α2-δ proteins define a novel class of centrally-acting drugs that are fundamentally different from other kinds of anticonvulsant, analgesic or anxiolytic drugs. It is thought that these α2-δ ligand drugs act by reducing the synaptic release of excitatory neurotransmitters and neuromodulators in the brain or spinal cord, particularly when synapses are abnormally hyperactive, or when cytosolic proteins are phosphorylated by protein kinase C or protein kinase A activation.

AB - Overall, these presentations reviewed the current state of α2-δ biology and pharmacology. The presentations describing structure-activity studies and mutation studies of drug binding to α2-δ indicated that high-affinity binding of pregabalin and related compounds to α2-δ type 1 protein is necessary for pharmacological actions in models of analgesic, anxiolytic, and anticonvulsant action. These findings suggest that drugs that act by binding to the α2-δ proteins define a novel class of centrally-acting drugs that are fundamentally different from other kinds of anticonvulsant, analgesic or anxiolytic drugs. It is thought that these α2-δ ligand drugs act by reducing the synaptic release of excitatory neurotransmitters and neuromodulators in the brain or spinal cord, particularly when synapses are abnormally hyperactive, or when cytosolic proteins are phosphorylated by protein kinase C or protein kinase A activation.

KW - α-δ Proteins

KW - Analgesics

KW - Anticonvulsants

KW - Calcium channels

KW - Gabapentin

KW - Pregabalin

KW - R217A mice

UR - http://www.scopus.com/inward/record.url?scp=3042727921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042727921&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 183

EP - 188

JO - CNS Drug Reviews

JF - CNS Drug Reviews

SN - 1080-563X

IS - 2

ER -